Epizyme (United States)

Recent papers from Epizyme (United States)

1. Single amino acid substitution in DNA Polymerase I dramatically alters infection dynamics of bacteriophage T72026
2. Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket studyNature Communications · 2026
3. 2024 Annual Meeting of the International Network on Ectopic Calcification (INTEC)—Abstract ProceedingsGout Urate and Crystal Deposition Disease · 2025
4. RFdiffusion Exhibits Low Success Rate in De Novo Design of Functional Protein Binders for Biochemical Detection2025
5. Handmade green tea: Antioxidant content and activitySHILAP Revista de lepidopterología · 2024
6. Targeting the synthetic lethal relationship between FOCAD and TUT7 represents a potential therapeutic opportunity for TUT4/7 small molecule inhibitors in cancerMolecular Cancer Therapeutics · 2024
7. EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent mannerMolecular Cancer Research · 2024
8. Multi-omic Analysis of Human B-cell Activation Reveals a Key Lysosomal BCAT1 Role in mTOR Hyperactivation by B-cell receptor and TLR92024
9. Prion Seeding Activity in Plant Tissues Detected by RT-QuICPathogens · 2024
10. Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin LymphomaJCO Clinical Cancer Informatics · 2024
11. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor GenesCancer Research · 2023
12. EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes2023
13. Effects of food, fasting, and exercise on plasma pyrophosphate levels and ENPP1 activity in healthy adultsBone · 2023
14. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models2023
15. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1Blood · 2022
16. Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical StudiesACS Medicinal Chemistry Letters · 2022
17. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and UmbralisibAdvances in Therapy · 2022
18. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsScientific Reports · 2022
19. Metabolically-incorporated deuterium in myelin localized by neutron diffraction and identified by mass spectrometrySHILAP Revista de lepidopterología · 2022
20. Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib StudyClinical Lymphoma Myeloma & Leukemia · 2021